Download Collaborations with Princess Margaret Cancer Center

Princess Margaret Cancer Center
University of Toronto
Toronto, Canada
Wednesday, August 21, 13
Princess Margaret Cancer Center
Wednesday, August 21, 13
University Health Network
(Teaching Hospitals Part of University of Toronto)
• Princess Margaret Cancer Center
• Toronto General Hospital/TGRI
• Toronto Western Hospital/TWRI
• Toronto Rehab/TRI
Wednesday, August 21, 13
PMCC: Nestled In the Vibrant University
Avenue Community
•Samuel Lunenfeld Research Institute-Mt. Sinai
•Hospital for Sick Children
•University of Toronto
•Ontario Institute for Cancer Research
Wednesday, August 21, 13
CONFIDENTIAL
Wednesday, August 21, 13
PMCC Research: A Snapshot
• 63 Scientists and Senior Scientists
12 Affiliate and Assistant Scientists
165 Clinician-Investigators
• $122,557,000 external funding (2010/11)
• 815 publications (2010/11)
• 370 clinical trials involving 7,000 patients
- Home to NIH Phase I and II consortia
- Site for NIH Cancer Immunotherapy Network
Wednesday, August 21, 13
Comparative Publication Analysis
% Cited
% H ighly Cited Papers
% in H igh-­‐Impact Journals
120%
100%
80%
60%
40%
20%
0%
Dana Farber
Johns Hopkins
Mayo Clinic
MD Anderson
Sloan Kettering
U Washington
PMH/UHN
Higher-­‐Impact Journals
Represen'ng <2% of all journals, journals with a Cita'on-­‐to-­‐publica'ons ra'o of >5 are considered higher-­‐impact Journals
Cita6on
Bibliographic acknowledgement of the contribu'on of one work to another. The number of 'mes a work is referenced by others indicates its impact on a body of knowledge. Rates vary considerably by subject area.
Highly-­‐cited paper
Papers with a cita'on count placing it amongst the top 10% of papers published in the year and subject-­‐area (as per ESI). High-­‐impact groups commonly have 25%-­‐30% of papers achieving this standing
Wednesday, August 21, 13
Full Spectrum of Research
!
Basic
Wednesday, August 21, 13
! Translational
! Clinical
Organized To Foster Full Spectrum of Research
PMCC
Research
PMCC
Clinical
Dir: Dr. Benjamin Neel
Dir: Dr. Mary Gospodarowicz
Research Executive Council
Division Heads
Research Council on Oncology
Wednesday, August 21, 13
Strength In Key Research Areas
• Cancer Biology & Therapeutics
- Stem cells
(Dick, Neel, Iscove, Khokha, Keller)
- Cell and Matrix Biology
- Signal transduction
(Muthuswamy, Khokha, Stambolic)*
(Neel, Muthuswamy, Rottapel, Stambolic, Ikura,
Teidelman)
- Tumor hypoxia
(Wouters, Hill, Muthuswamy, Bristow)
- Structural biology
- Radiobiology
(Ikura, Arrowsmith, Prive)
(Bristow, Wouters, Hill, Koch)
- DNA damage and repair
Wednesday, August 21, 13
(Bristow, Koch)
Strength In Key Research Areas
• Cancer Genomics & Biomarkers
- Epigenetis
(Lupien, Arrowsmith, De Carvalho)
- Proteomics
(Moran, Kisslinger, Raught)
- Clinical Genomics
(Roehl, Pugh)*
- Computational Biology
Wednesday, August 21, 13
(Jurisca, Hoffman)*
Strength In Key Research Areas
• Immunology & Immuno Therapy
- Mak, Ohashi, Paige, Hirano, Naoto
• Imaging & Image guided therapeutics
- Jaffray, Zheng, Wilson, Vitkin
Wednesday, August 21, 13
Translation To Clinic at PMCC
Drug Development Program (Malcolm Moore)
•NIH Phase I Consortium (Lillian Siu)
•NIH Phase II Consortium (Amit Oza)
•Supported by AMPL, Pharmacology Lab
CCRU
•Supports all phases of clinical trials
•Biostatistics
•Cancer Registries
•Other Clinical Trials Support
18,000 patients/year; 12,000 with new cancers
Wednesday, August 21, 13
PMCC: A Long History of
Accomplishments
• Hematopoietic stem cells
• T cell receptor
• Leukemia (and Cancer) stem cells
• Mammographic Density and Breast Cancer
• Local Radiation for Breast Cancer
• Treatment standards for many other cancers
Wednesday, August 21, 13
PMCC Research: Nationally and
Internationally Recognized
• Lasker Award (Till, McCullough)
• Gairdner Award (Till, McCullough, Mak)
• G.H. Clowes Award (Dick)
• Nobel Award (Dick, Mak, Hill, Ikura)
• Dameshek Prize (Dick)
• E. Donnall Thomas Prize (Dick)
• NCIC Golden Jubilee Awards (Till, McCullough,
Dick)
Wednesday, August 21, 13
Our Strategic Plan:Personalized
Cancer Medicine
•Detect
!
•Diagnose
•Target
!
•Support
Wednesday, August 21, 13
Our Strategic Plan: Personalized
Cancer Medicine
• Detect
! > Molecular Imaging**
> Biomarkers
> Advanced Biobanking
• Diagnose
>Precision genomics**
>Advanced Molecular Pathology**
• Target
!
>Better cancer models**
>Better targets: high throughput screens/Epigenetics**/CSCs*
>Immune-therapy**
• Support
>Psychosocial Oncology/Survivorship
Wednesday, August 21, 13
The PMCC 5-Year Vision of
Personalized Cancer Medicine
•
Complete genomic characterization of every tumor
•
Pharmacogenomic characterization of each patient
(differences in drug response)
Personalized “targeted (new) therapies” (CSC, epigenetics,
signal transduction, computational biology)
•
•
•
(Re-) activating the patient's immune system against the
tumor (Immune Therapy)
Individualizing imaging of tumors (molecular imaging)
•
Personalized surgical and radiation therapy (imaged-guided
therapies)
•
Personalized management of symptoms of disease and
therapy-induced complications (psychosocial oncology,
survivorship)
Wednesday, August 21, 13